APA (7th ed.) Citation

JW, D., JR, M., AHM, B., RW, v. O., RR, A., & KW, D. (2023). Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy. Molecular therapy. Methods & clinical development, 31, 101117. https://doi.org/10.1016/j.omtm.2023.101117

Chicago Style (17th ed.) Citation

JW, Day, Mendell JR, Burghes AHM, van Olden RW, Adhikary RR, and Dilly KW. "Adeno-associated Virus Serotype 9 Antibody Seroprevalence for Patients in the United States with Spinal Muscular Atrophy." Molecular Therapy. Methods & Clinical Development 31 (2023): 101117. https://doi.org/10.1016/j.omtm.2023.101117.

MLA (9th ed.) Citation

JW, Day, et al. "Adeno-associated Virus Serotype 9 Antibody Seroprevalence for Patients in the United States with Spinal Muscular Atrophy." Molecular Therapy. Methods & Clinical Development, vol. 31, 2023, p. 101117, https://doi.org/10.1016/j.omtm.2023.101117.